Cambridge – Cresset, innovative provider of computational drug discovery and development solutions that accelerate research outcomes, have announced the appointment of David Newble as Group Chairman.
David was previously Non-Executive Director on the Cresset Board and will take over the role of Chairman from Dr Robert Scoffin, who remains Cresset CEO. David will focus on the continued evolution of the company and on scaling for future international expansion, progressing Cresset’s corporate structure, investor relations, and growth plans.
David has extensive experience leading life sciences businesses, public and private fundraising for technology companies, and returning significant value to shareholders. He has been on the Cresset board as Non-Executive Director since January 2021, and has also held other senior roles including CEO positions at SPT Labtech and TAP Biosystems (now part of Sartorius Stedim).
Commenting on the appointment, Robert Scoffin said, “we are delighted that, as part of our ambitious development plans, David is taking on the role of Cresset Group Chairman. We are excited about Cresset’s growth potential and are looking forward to David supporting us to build on our excellent foundations, as we continue to help drug discovery scientists innovate.”
David Newble added, “I am pleased to be working with Rob and the rest of the exceptional Cresset team as the company moves into its next phase of growth. With a market leading range of solutions, we are uniquely placed to deliver value to our customers and our stakeholders.”
